The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study

BACKGROUND: Niraparib is the only poly (adenosine diphosphate-ribose)-polymerase (PARP) inhibitor available as oral monotherapy for maintenance, regardless of BRCA mutational status. METHODS: This phase I, open-label, non-randomized, dose-escalation study was conducted in Japan using a 3 + 3 design....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Jpn J Clin Oncol
Main Authors: Yonemori, Kan, Shimizu, Toshio, Kondo, Shunsuke, Iwasa, Satoru, Koyama, Takafumi, Kitano, Shigehisa, Sato, Jun, Shimomura, Akihiko, Shibaki, Ryota, Suri, Ajit, Kase, Yoichi, Sumino, Shuuji, Tamura, Kenji, Yamamoto, Noboru
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8086052/
https://ncbi.nlm.nih.gov/pubmed/33621324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyab013
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados